355 related articles for article (PubMed ID: 25791984)
1. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Olson WH; Pollack CV
Hosp Pract (1995); 2015; 43(2):85-93. PubMed ID: 25791984
[TBL] [Abstract][Full Text] [Related]
2. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
[TBL] [Abstract][Full Text] [Related]
3. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
4. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
[TBL] [Abstract][Full Text] [Related]
5. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
Kahler ZP; Beam DM; Kline JA
Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
[TBL] [Abstract][Full Text] [Related]
6. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
7. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
[TBL] [Abstract][Full Text] [Related]
10. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
[TBL] [Abstract][Full Text] [Related]
11. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
14. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
16. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
18. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
19. Effect of different initial anticoagulant strategies on short-term outcome of patients with symptomatic DVT in China.
Fan F; Zou Y; Wang Y; Zhang P; Zhang Y; Song Q; Dart AM; Zou Y
Int J Clin Pract; 2021 Oct; 75(10):e14619. PubMed ID: 34235827
[TBL] [Abstract][Full Text] [Related]
20. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
